<img alt="" src="https://secure.wake4tidy.com/244317.png" style="display:none;">

15 of our clients most frequent asked questions (FAQ)


Publication of SimSearch study demonstrating values of AI in microscopy

We are happy to announce the official publication of the study "SimSearch: A Human-in-the-loop learning framework for fast detection of regions of interest in microscopy images”, demonstrating Vironova’s technology leadership in AI-based research...


Ida-Maria Sintorn promoted Professor at Uppsala University

Vironova is proud to announce the promotion of its Chief Technology Officer (CTO) Ida-Maria Sintorn to Professor of Computerized Image Processing at Uppsala University, Department of Information Technology, as of 1 July, 2022.  


Vironova in collaboration for simplified production of gene therapy vectors

GeneNova, a new innovation milieu with the goal to develop novel production methods for adeno-associated virus based gene therapies, has just been launched.  


Annual General Meeting 2022 - Vironova AB

2020-06-15: Shareholders of Vironova AB (publ), 556678-1463, are hereby summoned to our annual general meeting which will be held on July 15 , 2022, at 14:00 at the company´s premise at Gävlegatan 22, Stockholm.


Annual General Meeting 2022 for Vironova AB will be held July 15th

2020-06-14: The Annual General Meeting will be moved from June 30, 2022 to July 15, 2022 at 14.00. A new notice of the Annual General Meeting will be issued shortly. The Annual General Meeting will be held at the company's premises at Gävlegatan 22...


Vironova/Takeda study demonstrates a validated cryoTEM-based method to analyze genome packaging in recombinant AAVs

We are happy to present a joint Vironova/Takeda study (PLoS ONE 17(6): e0269139) demonstrating a validated cryogenic TEM-based (cryoTEM) method to visualize, quantify, and assess the genome packaging in recombinant adeno-associated virus (rAAV)...


New scientific publication showing Vironova’s technology leadership in AI research

New scientific publication showing Vironova’s technology leadership in AI research for bioimage applications and engagement in academic-industry collaboration. Access the paper ahead of publication.


Prevas acquires Vironova AB's subsidiary BitSim NOW AB

Prevas has signed an agreement for the acquisition of 100 percent of BitSim NOW AB. BitSim NOW is a consulting firm in Stockholm with 35 employees focusing on innovative product development.


Major shareholders in alignment to create a stronger Vironova

The Board of Directors has been in contact with the major shareholders and has decided in a positive spirit that it will work towards a broadening of the Board of Directors, increased financial information and a greater spread of Class A shares in...

1 2 3 4 5